Global Cardiac Biomarker Diagnostic Kits Market is anticipated to rise at a value CAGR of 4.75 % over 2019-2028. According to a study published by Insure Insights on the Global Cardiac Biomarker Diagnostic Kits Market. Cardiac Biomarker are generally endogenous products like enzymes, hormones released from heart during cardiac dysfunctions. These biomarkers help the healthcare professional to diagnose cardiac dysfunctions like myocardial infarction, acute coronary syndrome, etc. Government initiatives for better healthcare and the increasing funds from public-private organizations for research and development for better technology are expanding the market growth. The surge in Clinical trials for the identification of cardiac biomarkers for better diagnosis has boosted the market revenue.

Top Driver: The surge in Cardiovascular disorders around the globe are driving market growth.

The rise in the occurrence of Cardiovascular disorders, like myocardial infarction angina pectoris, etc. around the globe and lifestyle habits like smoking and consumption of alcohol are the primary factors driving the market growth. The surge in the elderly population and technological advancements in cardiac diagnosis, sophisticated healthcare infrastructure have propelled the growth of the market. The advent of POC diagnostics kits has further driven the growth of the market.

Troponin test kits have made the highest segmental growth in the Global Cardiac Biomarker Diagnostic Kits Market

Based on the Product, Troponin test kits segment have dominated the segmental growth as they are considered as the most sensitive test kit, and thus, they are mostly preferred by the medical professionals for the diagnosis of cardiovascular diseases. They are the most efficient and provide accurate diagnosis of cardiovascular disorders as compared with other products

   In terms of the Testing, POC diagnostics segment has obtained due to the rise in the demand for POC testing, especially in the developed countries, POC test kits are small, handy, and they are more convenient to use and thus have improved the market growth. Based on the End User, Hospitals segment have held the most significant growth due to the availability of advanced instruments for cardiac diagnosis, increase in the healthcare expenditure, and enhanced patient care in hospitals have further driven the market

North America boosts the regional market due to the presence of key players  

The presence of key players in the region has positively influenced the regional growth. The rise in the research and development activities by the players and government initiatives for cardiovascular diagnosis and treatments have enhanced the overall regional growth. The rise in the incidences of cardiac diseases, in the region, the presence of sophisticated health care infrastructure, and increase in health care expenditure have escalated the market growth.

Product launches, new innovations, Mergers, and Acquisition, are the key strategies of the competitors

The Players of the Global Cardiac Biomarker Diagnostic Kits Market is fragmented. Product launches, new innovations, Mergers, and Acquisition, are strategies used by the competitors   The key competitors of the Global Cardiac Biomarker Diagnostic Kits Market are Hoffmann-La Roche AG, Bio-Rad Laboratories, Danaher Corporation, Abbott Laboratories, Seimens Healthineers, Thermofisher Scientific, bioMérieux, Randox Laboratories Ltd., and Ortho Clinical Diagnostics.

Seimens Healthineers:  Seimens Healthineers, is one of the key competitors of the Global Cardiac Biomarker Diagnostic Kits Market; for instance, In July 2018, Seimens Healthineers, had announced that the he U.S. Food and Drug Administration (FDA) cleared Siemens Healthineers high-sensitivity troponin I assay (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers. It was designed for early diagnosis of myocardial infarction.

Thermofisher Scientific:  Thermofisher Scientific is a popular competitor in the Global Cardiac Biomarker Diagnostic Kits Market. In March 2020, Boston Scientific Corporation had announced the acquisition of QIAGEN N.; they are involved in the manufacturing of the minimally invasive device. The acquisition was made by Thermofisher Scientific to expands its product portfolio with attractive molecular diagnostics capabilities, including infectious disease testing. 

Scope of the Report

By Product

• Troponin test kits
• CK-MB test kits
• Other Test kits

By Testing

• Laboratory testing
• Point of care testing

By End User

• Hospitals
• Diagnostics centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• LAMEA

Key Reasons to Purchase this Report

1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.